Fig. 3: Carbidopa decreases AR protein levels through ubiquitin-proteasome pathway. | Oncogenesis

Fig. 3: Carbidopa decreases AR protein levels through ubiquitin-proteasome pathway.

From: Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor

Fig. 3

a Immunoblot analysis of AR and PSA. LNCaP cells were treated with increasing doses of Carbidopa for 24 h. b Quantitative analysis of each immunoblot; results were normalized to control and data are given as means ± SEM. *p < 0.05 versus control. **p < 0.01 versus control. c RT-PCR analysis of AR mRNA. d Quantitative RT-PCR analysis of AR mRNA level. LNCaP cells were treated with Carbidopa for 24 h. GAPDH was used as the loading control. Results were normalized to control and data are given as means ± SEM. e Immunoblot analysis of AR. LNCaP cells were incubated in the presence or absence of Carbidopa (100 μM) for 24 h, and in the final 6 h of treatment, the cells were treated with or without 10 μM MG132. f Quantitative analysis of each immunoblot; results were normalized to control and data are given as means ± SEM of three independent experiments. *p < 0.05 versus control. #p < 0.05 versus Carbidopa treatment. g LNCaP cells were incubated in the presence or absence of Carbidopa (100 μM) for 24 h. AR was immunoprecipitated, and the immunoprecipitated was then used for immunoblot to analyze ubiquitinated AR.

Back to article page